Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/23218766http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/23218766http://www.w3.org/2000/01/rdf-schema#comment"

Background

Expression of class ΙΙΙ β-tubulin (βΙΙΙ-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several human malignancies including breast cancer. However its predictive value in a neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether βΙΙΙ-tubulin expression in breast cancer correlated with pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy.

Patients and methods

We determined βΙΙΙ-tubulin expression in 85 breast cancers, including 41 localized breast cancers treated with primary surgery and 44 treated with neoadjuvant chemotherapy before surgery. βΙΙΙ-tubulin expression was evaluated by immunohistochemical methods and was correlated with pathologic characteristics and response to neoadjuvant chemotherapy using residual cancer burden (RCB) score.

Results

High βΙΙΙ-tubulin expression was significantly associated with poorly differentiated high-grade breast cancers (P = .003) but not with tumor size, estrogen receptor (ER) status, or human epidermal growth factor receptor 2 (HER2)/neu overexpression. In ER(-) tumors treated with neoadjuvant chemotherapy, high βΙΙΙ-tubulin expression was associated with a significantly greater likelihood of achieving a good pathologic response to chemotherapy as reflected by lower RCB scores (P = .021).

Conclusion

This study reveals differential βΙΙΙ-tubulin expression in breast cancers of different histologic grades, hormone receptors, and HER2/neu status. It also suggests a potential role for βΙΙΙ-tubulin as a predictive biomarker for response in neoadjuvant chemotherapy for ER(-) breast cancer, which has not been previously reported. These data provide a strong rationale for considering βΙΙΙ-tubulin status and further validation of this marker in a large study."xsd:string
http://purl.uniprot.org/citations/23218766http://purl.org/dc/terms/identifier"doi:10.1016/j.clbc.2012.11.003"xsd:string
http://purl.uniprot.org/citations/23218766http://purl.uniprot.org/core/author"Wang Y."xsd:string
http://purl.uniprot.org/citations/23218766http://purl.uniprot.org/core/author"Sparano J.A."xsd:string
http://purl.uniprot.org/citations/23218766http://purl.uniprot.org/core/author"Horwitz S.B."xsd:string
http://purl.uniprot.org/citations/23218766http://purl.uniprot.org/core/author"McDaid H.M."xsd:string
http://purl.uniprot.org/citations/23218766http://purl.uniprot.org/core/author"Fineberg S."xsd:string
http://purl.uniprot.org/citations/23218766http://purl.uniprot.org/core/author"Stead L."xsd:string
http://purl.uniprot.org/citations/23218766http://purl.uniprot.org/core/author"Sunkara J."xsd:string
http://purl.uniprot.org/citations/23218766http://purl.uniprot.org/core/date"2013"xsd:gYear
http://purl.uniprot.org/citations/23218766http://purl.uniprot.org/core/name"Clin Breast Cancer"xsd:string
http://purl.uniprot.org/citations/23218766http://purl.uniprot.org/core/pages"103-108"xsd:string
http://purl.uniprot.org/citations/23218766http://purl.uniprot.org/core/title"High expression of class III beta-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer."xsd:string
http://purl.uniprot.org/citations/23218766http://purl.uniprot.org/core/volume"13"xsd:string
http://purl.uniprot.org/citations/23218766http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/23218766
http://purl.uniprot.org/citations/23218766http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/23218766
http://purl.uniprot.org/uniprot/#_A0A0B4J269-mappedCitation-23218766http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/23218766
http://purl.uniprot.org/uniprot/#_B2RBD5-mappedCitation-23218766http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/23218766
http://purl.uniprot.org/uniprot/#_Q13509-mappedCitation-23218766http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/23218766
http://purl.uniprot.org/uniprot/#_Q3ZCR3-mappedCitation-23218766http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/23218766
http://purl.uniprot.org/uniprot/#_Q53G92-mappedCitation-23218766http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/23218766
http://purl.uniprot.org/uniprot/#_Q9BV28-mappedCitation-23218766http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/23218766
http://purl.uniprot.org/uniprot/Q13509http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/23218766
http://purl.uniprot.org/uniprot/Q9BV28http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/23218766
▶